✦ LIBER ✦

41* PTC124 activity in CF patients carrying stop mutations: results of a phase 2 study

✍ Scribed by E. Kerem; S. Hirawat; S. Armoni; Y. Yaakov; H. Blau; J. Rivlin; M. Aviram; D. Shoseyov; M. Cohen; V. Northcutt; G. Elfring; L. Miller; M. Wilschanski

Book ID: 118641099
Publisher: Elsevier Science
Year: 2007
Tongue: English
Weight: 62 KB
Volume: 6
Category: Article
ISSN: 1569-1993
DOI: 10.1016/s1569-1993(07)60034-4

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

P3.51 Results of a Phase 2b, dose-rangin

P3.51 Results of a Phase 2b, dose-ranging study of ataluren (PTC124®) in nonsense mutation Duchenne/Becker muscular dystrophy (nmDBMD)

✍ R. Finkel; B. Wong; K. Bushby; A. Reha; G.L. Elfring; L.L. Miller; J. Babiak; M. 📂 Article 📅 2010 🏛 Elsevier Science 🌐 English ⚖ 50 KB

P.11.19 Phase 2b, dose-ranging study of

P.11.19 Phase 2b, dose-ranging study of ataluren (PTC124®) innonsense mutation Duchenne muscular dystrophy – results of a post hoc analysis of change in %-predicted 6-min walk distance

✍ McDonald, C.M.; Henricson, E.K.; Abresch, R.T.; Elfring, G.L.; Barth, J.; Peltz, 📂 Article 📅 2013 🏛 Elsevier Science 🌐 English ⚖ 50 KB

One in 10 ovarian cancer patients carry

One in 10 ovarian cancer patients carry germ line BRCA1 or BRCA2 mutations: results of a prospective study in Southern Sweden

✍ S. Malander; M. Ridderheim; A. Måsbäck; N. Loman; U. Kristoffersson; H. Olsson; 📂 Article 📅 2004 🏛 Elsevier Science 🌐 English ⚖ 197 KB

M.P.3.05 Use of a novel system for gradi

M.P.3.05 Use of a novel system for grading timed function test performance in phase 2b study of ataluren (PTC124™) in nonsense mutation Duchenne and Becker muscular dystrophy (nmDMD/BMD)

✍ M. Elfring; R.T. Abresch; J. Florence; E. Gappmaier; A.M. Glanzman; E. Henricson 📂 Article 📅 2009 🏛 Elsevier Science 🌐 English ⚖ 43 KB

124 Activity and safety of the investiga

124 Activity and safety of the investigational agent orteronel (ortl, TAK-700) in men with nonmetastatic castration-resistant prostate cancer (CRPC) and rising prostate-specific antigen (PSA): Results of a phase 2 study

✍ M. Hussain; P. Corn; D. Michaelson; H. Hammers; J. Alumkal; C. Ryan; J. Bruce; S 📂 Article 📅 2012 🏛 Elsevier Science 🌐 English ⚖ 73 KB

Final results of a multicenter phase II

Final results of a multicenter phase II clinical trial evaluating the activity of single-agent lapatinib in patients with HER2-negative metastatic breast cancer and HER2-positive circulating tumor cells. A proof-of-concept study

✍ Marta Pestrin, Silvia Bessi, Fabio Puglisi, Alessandro M. Minisini, Giovanna Mas 📂 Article 📅 2012 🏛 Springer US 🌐 English ⚖ 246 KB